On the viral safety of plasma pools and plasma derivatives

Journal of the Royal Statistical Society. Series A: Statistics in Society

Volumn 168, Issue 2, 2005, Pages 345-363

  Vansteelandt, S ^a   Goetghebeur, E ^a,b   Thomas, I ^c   Mathys, E ^c   Van Loock, F ^c  

^a GHENT UNIVERSITY   (Belgium)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

Author keywords

Dilution; Group test; Holding period; Plasma derivatives; Pooling; Transmission

Indexed keywords

EID: 15844409801     PISSN: 09641998     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1467-985X.2005.00352.x     Document Type: Article

References (28)

1. Albadalejo, J., Alonso, R., Antinozzi, R., Bogard, M., Bourgault, A. M., Colucci, G., Fenner, T., Petersen, H., Sala, E., Vincelette, J. and Young, C. (1998) Multicenter evaluation of the COBAS AMPLICOR HCV assay, an integrated PCR system for rapid detection of hepatitis C virus RNA in the diagnostic laboratory. J. Clin. Microbiol., 36, 862-865.
2. Barrera, J. M., Francis, B., Ercilla, G., Nelles, M., Achord, D., Darner, J. and Lee, S. R. (1995) Improved detection of anti-hcv in posttransfusion hepatitis by a 3rd-generation ELISA. Vox Sang., 68, 15-18.
3. Behets, F., Bertozzi, S., Kasali, M., Kashamuka, M., Atikala, L., Brown, C., Ryder, R. W. and Quinn, T. C. (1992) Successful use of pooled sera to determine HIV-1 seroprevalence in Zaire with development of cost-efficiency models. AIDS, 4, 737-741.
4. Couroucé, A.-M., Le Marrec, N., Girault, A., Ducamp, S. and Simon, N. (1994) Anti-hepatitis C virus (anti-HCV) seroconversion in patients undergoing hemodialysis: comparison of 2nd-generation and 3rd-generation anti-HCV assays. Transfusion, 34, 790-795.
5. Cox, D. R. (1962) Renewal Theory. London: Wiley.
6. Dodd, R. Y., Notari IV, E. P. and Stramer, S. L. (2002) Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion, 42, 975-979.
7. Flanagan, P. (1999) Genomic screening of blood donations - the new Dawn arrives. Vox Sang., 76, 135-137.
8. Hung, M. and Swallow, W. H. (1999) Robustness of group testing in the estimation of proportions. Biometrics, 55, 231-237.
9. Kaplan, E. H. (2001) Evaluating plasma holds in the presence of multiple infections. IMA J. Math. Appl. Med. Biol., 18, 215-224.
10. Kaplan, E. H. and Satten, G. A. (1999) Hold everything!: holding policies for protecting plasma supplies. Math. Biosci., 160, 159-173.
11. Lackritz, E. M., Satten, G. A., Aberle-Grasse, J., Dodd, R. Y., Raimondi, V. P., Janssen, R. S., Lewis, W. F., Notari IV, E. P. and Petersen, L. R. (1995) Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. New Engl. J. Med., 333, 1721-1725.
12. Lauer, G. M. and Walker, B. D. (2001) Medical progress: hepatitis C virus infection. New Engl. J. Med., 345, 41-52.
13. Lefrère, J.-J., Coste, J., Defer, C., Mercier, B., Férec, C., Loiseau, P., Portelette, E., Mariotti, M., Lerable, J., Rouger, P. and Pawlotsky, J.-M. (1998) Screening blood donations for viral genomes: multicenter study of real-time simulation using pooled samples on the model of hepatitis C virus RNA detection. Transfusion, 38, 915-922.
14. Lelie, P. N., Cuypers, H. T. M., Rogers, P., Over, J., Schuitemaker, J. and Quint, W. G. V. (1997) Standardisation of viral nucleic acid amplification methodology in blood safety testing: a risk benefit analysis. Technical Report. Viral Diagnostic Laboratory, Amsterdam.
15. Mortimer, J. (1997) Intersecting pools and their potential application in testing donated blood for viral genomes. Vox Sang., 73, 93-96.
16. Müller-Breitkreutz, K. (2000) Results of viral marker screening of unpaid blood donations and probability of window period donations in 1997. Vox Sang., 78, 149-157.
17. National Institutes of Health (1998) Report of the Expert Panel on Donor Pool Size of Immunoglobulin Products. Report. National Institutes of Health, Bethesda. (Available from www.niaid.nih.gov/dait/ivig1.html.)
18. Pereira, A. and Sanz, C. (2000) A model of the health and economic impact of posttransfusion Hepatitis C: application to cost-effectiveness analysis of further expansion of HCV screening protocols. Transfusion, 40, 1182-1191.
19. Rode Kruis Vlaanderen (2000) Jaarverslag 1999, pp. 21-30. Brussels: Red Cross Flanders.
20. Rode Kruis Vlaanderen (2002) Jaarverslag 2001, pp. 21-30. Brussels: Red Cross Flanders.
21. Satten, G. A. (1997) Steady-state calculation of the risk of HIV infection from transfusion of screened blood from repeat donors. Math. Biosci., 141, 101-113.
22. Saura, C., Couroucé, A. M., Pillonel, J., Costagliola, D., Flan, B., Defer, C., Coste, J. and Rouzioux, C. (1999) Risk-benefit analysis of nucleic acid testing: the French experience. Biologicals, 27, 343-348.
23. Schafer, D. F. and Sorrell, M. F. (2000) Conquering hepatitis C, step by step. New Engl. J. Med., 343, 1723-1724.
24. Schreiber, G. B., Busch, M. P., Kleinman, S. H. and Korelitz, J. J. (1996) The risk of transfusion-transmitted viral infections. New Engl. J. Med., 334, 1685-1690.
25. Thomas, I., Branckaert, T., Mathys, E., Vranckx, R. and Laub, R. (2000) PCR detects HCV RNA in a plasma pool contaminated by a single preseroconversion donation of genotype 5a. Vox Sang., 79, 69-71.
26. Thomas, I., Mathys, E. and Gerard, C. (2002) The use of nucleic acid amplification techniques to increase the viral safety of blood. Clin. Lab., 48, 155-160.
27. United States General Accounting Office (1998) Blood plasma safety: plasma product risks are low if good manufacturing practices are followed. Report GAO/HEHS-98 205. United States General Accounting Office, Washington DC.
28. Willkommen, H., Schmidt, I. and Löwer, J. (1999) Safety issues for plasma derivatives and benefit from NAT testing. Biologicals, 27, 325-331.